Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Dianthus Therapeutics — Merger or Acquisition (October 2025)
19 slides from Dianthus Therapeutics's merger presentation, Oct 16, 2025
Slide 1: Licensing of DNTH212 (BDCA2 and BAFF/APRIL) from Leads Biolabs
Dianthus Therapeutics Licensing of DNTH212 (BDCA2 and BAFF/APRIL) from Leads Biolabs October 16, 2025 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities
Slide 3: Agenda
Introduction Marino Garcia, Chief Executive Officer DNTH212 Opportunity Overview Simrat Randhawa, MD, Head of Research & Development Deal Terms & Strategic Perspectives Ryan Savitz, Chief Financial Officer & Chief Business Officer Marino Garcia, Chief Executive Officer Q&A Marino Garcia, Chief Execu
Slide 4: DNTH212 license expands leadership in next-generation therapeutics
DNTH212 (BDCA2 and BAFF/APRIL inhibitor) expands leadership in next-generation therapeutics Entered into an exclusive license agreement with Leads Biolabs for global rights (ex-Greater China1) for DNTH212, a first and potentially best-in-class, Ph. 1 ready bifunctional BDCA2 and BAFF/APRIL inhibitor
Slide 5: Opportunity Overview
DNTH212 Opportunity Overview
Slide 6: DNTH212 is a bifunctional BDCA2 and BAFF/APRIL inhibitor targeting two well-validated pathways
Inhibiting BDCA2 reduces Type 1 interferon production from plasmacytoid dendritic cells (pDCs) Single CRD2 domain of TACI designed to deliver robust B cell modulation via BAFF/APRIL inhibition DNTH212 targets both the innate and adaptive immune systems with complementary disease modifying mechanisms
Slide 7: Potential to drive superior efficacy by targeting innate and adaptive immune systems
Potential to drive superior clinical efficacy by targeting both the innate and adaptive immune systems Panda SK, et al., Plasmacytoid dendritic cells in autoimmunity. Curr Opin Immunol. 2017 Feb;44:20-25. Minaga K, et al., Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune. Fron
Slide 8: DNTH212 achieves superior pDC depletion compared to litifilimab in vitro
DNTH212 achieves superior pDC depletion compared to litifilimab in vitro Comparable Suppression of Pro-Inflammatory Cytokine IFN-α1 Deeper Depletion of pDC2 Method: Human PBMCs from a healthy donor were co-cultured with a TLR9 agonist and serially diluted antibodies for 24 hours. IFN-α release in th
Slide 9: DNTH212 shows superior inhibition of IgM, IgA, and IgG compared to povetacicept in NHPs
DNTH212 shows superior inhibition of IgM, IgA, and IgM compared to povetacicept following single dose in NHPs S.C. DNTH212 IV povetacicept and telitacicept1 Note: These data are derived from different studies at different points in time, with differences in methodology, design and populations. As a
Slide 10: Validation of BDCA2 and BAFF/APRIL targeted therapies supports bifunctional approach
Validation of both BDCA2 and BAFF/APRIL targeted therapies support DNTH212 bifunctional approach Note: Company press releases and investor presentations Positive Litifilimab (BDCA2) Data in SLE / CLE BAFF/APRIL Validation Across Multiple Autoimmune Indications and Strategic Activity
Slide 11: Broad opportunity for DNTH212 across multiple autoimmune diseases
Biological Rationale Clinical Evidence Primary Sjögren's Syndrome ~350,000 U.S. Patients B Cell: ianalumab positive Ph. 3; telitacicept positive Ph. 3 Cutaneous Lupus Erythematosus ~300,000 U.S. Patients Type 1 interferon: litifilimab positive Ph. 2 Systemic Lupus Erythematosus ~225,000 U.S. Pat
Slide 12: Expect to start Ph. 1 study in China in Q4'25
Expect to start Ph. 1 study in China in Q4’25 with top-line Part A HV results in 2H’26 5mg N = 2:0 S.C. Administration Healthy Volunteers (Part A) ~46 HVs enrolled into seven cohorts: Treated (N= up to 6) Placebo (N= up to 2) ~30 patients enrolled into three cohorts: Treated (N= up to 10) Healthy Vo
Slide 13: Target product profile for DNTH212
DNTH212 TPP aims to deliver superior efficacy in a safe and well-tolerated therapy with patient friendly convenience Achieving the TPP would position DNTH212 as a first-line biologic across a range of indications Bifunctional approach has potential for superior efficacy in various disease states ver
Slide 14: Expands Leadership in Next-generation Therapeutics for Severe Autoimmune Diseases
DNTH212 Expands Leadership in Next-generation Therapeutics for Severe Autoimmune Diseases
Slide 15: Favorable upfront and near-term economics with cash runway into 2028
Favorable upfront and near-term economics with no impact on previously guided cash runway into 2028 Up to $38M comprised of $30M in upfront and near-term milestone payments plus an additional $8M milestone upon the initiation of a Dianthus-led Phase 1 study Future Milestone Payments Upfront and Near
Slide 16: DNTH212 expands our leadership in next-generation therapeutics
DNTH212 expands our leadership in next-generation therapeutics with best-in-class potential Value Proposition Claseprubart DNTH212 Validated Mechanism of Action(s) aC1s: gMG, CIDP Classical Pathway: gMG, CIDP, MMN BDCA2: SLE, CLE BAFF/APRIL: SLE, Sjögren’s, IgAN, MG, RA Best-in-class Potential Super
Slide 17: Achieving DNTH212 TPP would position it as first-line, best-in-class therapy
Achieving DNTH212 TPP would position DNTH212 as a first-line, best-in-class therapy across multiple indications Type 1 interferon and BAFF/APRIL are known drivers of autoimmune disease Potential S.C. self-administration Q4W or less frequent Targeting innate and adaptive immune systems has potential
Slide 18: DNTH212 bolsters pipeline and builds on vision of leading in severe autoimmune diseases
DNTH212 bolsters pipeline and builds on our vision of being a leader in severe autoimmune diseases gMG: >100,000 gMG U.S. patients from Komodo claims data accessed 2013-2025; approx. 85% of gMG patients have AChR autoantibody-driven disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033452/# CIDP
Slide 19: Q&A
October 16, 2025 Q&A Licensing of DNTH212 (BDCA2 and BAFF/APRIL) from Leads Biolabs
Dianthus Therapeutics — Merger or Acquisition (October 2025) on 6ix